Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NT-proBNP-guided prevention of cardiac events in type 2 diabetes without known cardiac disease
2024-519051-28-01Phase 4Completed
- Sponsor
- Medical University of Vienna
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 4, randomised trial of ramipril in type 2 diabetes mellitus (T2DM), cardiac morbidity and heart failure (HF) (2 arms), sponsored by Medical University of Vienna. Primary endpoint: Primary combined cardiac endpoint. Started Feb 2025; status: completed.
02
Drugs
ramipril
03
Conditions
type 2 diabetes mellitus (T2DM)cardiac morbidityheart failure (HF)
Beyond the preview
Go deeper on 2024-519051-28-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519051-28-01.